A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

BACKGROUND. We assessed the efficacy and safety of bevacizumab (BEV) through multiple lines in patients with recurrent glioblastoma who had progressed after first‐line treatment with radiotherapy, temozolomide, and BEV. PATIENTS AND METHODS. TAMIGA (NCT01860638) was a phase II, randomized, double‐bl...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Brandes, Alba A., Gil‐Gil, Miguel, Saran, Frank, Carpentier, Antoine F., Nowak, Anna K., Mason, Warren, Zagonel, Vittorina, Dubois, François, Finocchiaro, Gaetano, Fountzilas, George, Cernea, Dana Michaela, Chinot, Oliver, Anghel, Rodica, Ghiringhelli, Francois, Beauchesne, Patrick, Lombardi, Giuseppe, Franceschi, Enrico, Makrutzki, Martina, Mpofu, Chiedzo, Urban, Hans‐Joerg, Pichler, Josef
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2018
Konular:
Neuro‐Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459244/
https://ncbi.nlm.nih.gov/pubmed/30266892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0290
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller